Vivimed Labs share news, announcements and annual reports
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.53down ₹0.11 (1.95%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹5.64.
30 Oct: open ₹5.62, high ₹5.64, low ₹5.53
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,267
Vivimed Labs orders, deals and press releases
36 filed, newest first.
May 2021
Apr 2021
Mar 2021
8 Mar · Business
4 Mar · Business
Feb 2021
Nov 2020
Oct 2020
Aug 2020
May 2019
8 May · Business
Jan 2019
Dec 2018
Oct 2018
5 Oct · Business
May 2018
Feb 2018
Jan 2018
Sep 2017
Jun 2017
May 2017
Jan 2017
Nov 2016
29 Nov · Business
Jul 2016
Sep 2015
May 2014
Sep 2013
11 Sep · Business
At the meeting of Management Committee of Board of Directors of 'Vivimed Labs Limited' held on September 10, 2013 has allotted 142,857 equity shares of the Company to (1) Dr. Kumar Kurumaddali and (2) Mrs. Prashanthi Alamuru [Swap of shares of FINOSO PHARMA PVT LTD - acquired by VIVIMED LABS LTD].
Mar 2013
22 Mar · Business
Management Committee of the Board of Directors of the Company at its meeting held on March 22, 2013, has allotted 21,26,984 Equity Shares of Rs.10/- each fully paid up at a premium of Rs.305/- per share to NYLIM Jacob Ballas India FUND III, LLC (Address : IFS Court, Twentyeight, Cybercity, Ebene, Mauritius) against conversion of 6,70,000 CCPS (face value Rs. 1000/- each) held by them. With the allotment of the said shares, the Equity base of the Company stands increased from present level of 139,33,942 (Nos.) to 160,60,926 (Nos.) Equity shares of Rs.10/- each.
Sep 2011
29 Sep · Business
Management Committee of Board of Directors of the Company at their meeting held on September 29, 2011 has allotted 1830137 Equity Shares of Rs.10/- to Kitara PIIN 1102.23 Sep · Business
Management Committee of Board of Directors of the Company at their meeting held on September 22, 2011, has allotted 6,70,000 Compulsorily Convertible and Cumulative Preference Shares (CCPSs) of Rs. 1000/- to Nylim Jacob Ballas India Fund III LLC.
Jul 2011
12 Jul · Business
Management Committee of the Board of Directors of the Company at their meeting held on July 11, 2011 have allotted 4,49,789 equity shares on preferential basis pursuant to (1) Special Resolution passed by the shareholders of the Company at their extra ordinary general meeting held on June 20, 2011, under Section 81 (1A) of Companies Act, 1956 and the Preferential Issue Regulations under Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended from time to time. (2) Agreement and Plan of merger by and between Vivimed Labs Ltd, Vivimed Labs USA Inc., Har-Met International Inc., Mr. William F. Harvey and Mr. Arvind Mehta (Mr. William F. Harvey and Mr. Arvind Mehta being shareholders of Har-Met International Inc.) , dated August 03, 2009.
Oct 2010
4 Oct · Business
Management Committee of the Board of Directors of the Company has allotted 199,112 differential Equity Shares against conversion of Foreign Currency Convertible Bonds.
Dec 2008
23 Dec · Business
Board of Directors of Vivimed Labs Limited has discussed and gave its approval for the Agreement and Plan of merger being entered into with Har-met International Inc, USA and there by for the acquisition of Har-met International Inc, USA subject to consents/ permissions/ sanctions as may be required from concerned authorities, Stock Exchanges and/ or members of the Company.
Feb 2008
11 Feb · Business
Board of directors of the Company at it's Board meeting held on 09th February, 2008 had taken following decisions inter alia among others:- Considered the proposal for acquisition of shares of James Robinson Limited and other associated assets (together "James Robinson") from Yule Catto & Co plc subjected to consents/permissions/sanctions as may be required from concerned authorities, Stock Exchanges and/or members of the Company.